Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus
Giovanni Targher, Amedeo Lonardo, Christopher D. Byrne
Nature Reviews Endocrinology (2017) Vol. 14, Iss. 2, pp. 99-114
Closed Access | Times Cited: 357

Showing 1-25 of 357 citing articles:

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
François Mach, Colin Baigent, Alberico L. Catapano, et al.
European Heart Journal (2019) Vol. 41, Iss. 1, pp. 111-188
Open Access | Times Cited: 6803
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
François Mach, Colin Baigent, Alberico L. Catapano, et al.
Atherosclerosis (2019) Vol. 290, pp. 140-205
Open Access | Times Cited: 4150
Molecular mechanisms and physiological functions of mitophagy
Mashun Onishi, Koji Yamano, Miyuki Sato, et al.
The EMBO Journal (2021) Vol. 40, Iss. 3
Open Access | Times Cited: 920
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Kenneth Cusi, Scott Isaacs, Diana Barb, et al.
Endocrine Practice (2022) Vol. 28, Iss. 5, pp. 528-562
Open Access | Times Cited: 631
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2020) Vol. 69, Iss. 9, pp. 1691-1705
Open Access | Times Cited: 571
The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments
Giovanni Targher, Kathleen E. Corey, Christopher D. Byrne, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 9, pp. 599-612
Closed Access | Times Cited: 569
Complications, morbidity and mortality of nonalcoholic fatty liver disease
Alessandro Mantovani, Eleonora Scorletti, Antonella Mosca, et al.
Metabolism (2020) Vol. 111, pp. 154170-154170
Open Access | Times Cited: 437
Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Gut (2020) Vol. 70, Iss. 5, pp. 962-969
Open Access | Times Cited: 352
FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption
Bethan L. Clifford, Leslie R. Sedgeman, Kevin J. Williams, et al.
Cell Metabolism (2021) Vol. 33, Iss. 8, pp. 1671-1684.e4
Open Access | Times Cited: 276
Role of Insulin Resistance in MAFLD
Yoshitaka Sakurai, Naoto Kubota, Toshimasa Yamauchi, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 8, pp. 4156-4156
Open Access | Times Cited: 265
How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
Yana Geng, Klaas Nico Faber, Vincent E. de Meijer, et al.
Hepatology International (2021) Vol. 15, Iss. 1, pp. 21-35
Open Access | Times Cited: 244
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Sven Francque, Gyöngyi Szabó, Manal F. Abdelmalek, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 18, Iss. 1, pp. 24-39
Closed Access | Times Cited: 240
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Kalliopi Pafili, Michael Roden
Molecular Metabolism (2020) Vol. 50, pp. 101122-101122
Open Access | Times Cited: 235
Mitochondrial Stasis Reveals p62-Mediated Ubiquitination in Parkin-Independent Mitophagy and Mitigates Nonalcoholic Fatty Liver Disease
Tatsuya Yamada, Daisuke Murata, Yoshihiro Adachi, et al.
Cell Metabolism (2018) Vol. 28, Iss. 4, pp. 588-604.e5
Open Access | Times Cited: 229
Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease
M Alexander, A. Katrina Loomis, Jolyon Fairburn-Beech, et al.
BMC Medicine (2018) Vol. 16, Iss. 1
Open Access | Times Cited: 225
Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Metabolites (2021) Vol. 11, Iss. 2, pp. 73-73
Open Access | Times Cited: 212
Nonalcoholic fatty liver disease and Type 2 diabetes mellitus
Mala Dharmalingam, P Ganavi Yamasandhi
Indian Journal of Endocrinology and Metabolism (2018) Vol. 22, Iss. 3, pp. 421-421
Open Access | Times Cited: 196
Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review
Alessandro Mantovani, Christopher D. Byrne, Giovanni Targher
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 4, pp. 367-378
Open Access | Times Cited: 165
Treatments for NAFLD: State of Art
Alessandro Mantovani, Andrea Dalbeni
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 5, pp. 2350-2350
Open Access | Times Cited: 160
Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations
Ramesh Kumar, Rajeev Nayan Priyadarshi, Utpal Anand
Journal of Clinical and Translational Hepatology (2019) Vol. X, Iss. X, pp. 1-11
Open Access | Times Cited: 153
The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk
Cyrielle Caussy, Adrien Aubin, Rohit Loomba
Current Diabetes Reports (2021) Vol. 21, Iss. 5
Open Access | Times Cited: 146
The role of hepatokines in NAFLD
Norbert Stefan, Fritz Schick, Andreas L. Birkenfeld, et al.
Cell Metabolism (2023) Vol. 35, Iss. 2, pp. 236-252
Open Access | Times Cited: 135
Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver
Eda Kaya, Yusuf Yılmaz
Journal of Clinical and Translational Hepatology (2021) Vol. 10, Iss. 2, pp. 329-338
Open Access | Times Cited: 117
Polyol pathway and redox balance in diabetes
Sourbh Suren Garg, Jeena Gupta
Pharmacological Research (2022) Vol. 182, pp. 106326-106326
Closed Access | Times Cited: 72
Management of diabesity: Current concepts
Maria Michaelidou, Joseph M. Pappachan, Mohammad Sadiq Jeeyavudeen
World Journal of Diabetes (2023) Vol. 14, Iss. 4, pp. 396-411
Open Access | Times Cited: 46
Page 1 - Next Page

Scroll to top